Tests duvakitug in adults with active Crohn's disease over time
Compares duvakitug with placebo in adults with moderately to severely active Crohn's disease.
Key facts
- Who runs it
- Sanofi
- Where
- Cape Town, Durban, and Kempton Park, South AfricaSee the 3 sitesAlso in 26 other countries, 106 sites
- Trial code
- NCT07184944
- EudraCT 2025-521037-86
- U1111-1314-5471
- Registry title
- A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 751 people, planned
- Started
- 22 Jan 2026
- Expected to end
- 20 Mar 2034
- Type of study
- Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Duvakitug
- Placebo
- Record updated
- 21 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with Crohn's disease who improved on the earlier STARSCAPE-1 study, to test duvakitug against placebo for keeping the disease under control.
- Age
- 18 to 80 years. Where local rules allow, 16 to under 18 years if development is at Tanner stage 5.
- Sex
- All sexes can join.
- Disease stage
- Crohn's disease that was moderately to severely active. People must have had a clinical response and an endoscopy at the end of STARSCAPE-1.
- Earlier treatment
- People must have finished the STARSCAPE-1 study. For the extension part, they must have finished the maintenance part or the TV48574-IMM-20038 study.
Main reasons for not taking part
- Medical or compliance conditions that the investigator finds unsuitable for the study
- Known hypersensitivity to duvakitug that the investigator finds unsuitable for the study
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Participants aged ≥18 and ≤80 years of age at Baseline. (Where locally permissible, participants 16 to <18 years of age who meet the definition of Tanner stage 5 for development)
- Pivotal Maintenance Sub-Study: Participants who achieved clinical response and completed endoscopy at the end of STARSCAPE-1
- OLE Sub-Study: Participants who complete the Pivotal Maintenance Sub-Study or participation in the TV48574-IMM-20038 Study
Who cannot take part
- Participants with medical or compliance conditions that are deemed unsuitable for the study by the investigator
- Participants with a known hypersensitivity to duvakitug that makes the participant unsuitable for the study by the investigator; The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 16 and 80 years old?
This trial is currently available in South Africa.
Also in 26 other countries, 106 sites
- Cape TownHospital not named in the registryTaking people
- DurbanHospital not named in the registryTaking people
- Kempton ParkHospital not named in the registryTaking people
About the trial
What the trial wants to find out
This is a multicenter, randomized, double-blind, placebo-controlled, maintenance, Phase 3 study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn's Disease (CD). Study details include:
Read full original descriptionShow less
The study duration may be up to 286 weeks including:
* 40-week Pivotal Maintenance Sub-Study * 240-week Open-Label Extension (OLE) Sub-Study * 45-day Follow-Up visit
Note: For the participants who do not enroll into OLE Sub-Study, the duration will be up to 46 weeks, including the 40-week maintenance period and a 45-day follow-up visit.
The treatment duration may be up to 280 weeks including:
* 40 weeks in the Pivotal Maintenance Sub-Study * 240 weeks in OLE Sub-Study
The total number of on-site visits will be up to 43: - 21 visits in the Pivotal Maintenance Sub-Study - 22 visits in the OLE Sub-Study
The 4 groups in the trial
- Duvakitug dose 1Treatment being tested
Subcutaneous (SC) injection as per protocol
Treatment: Duvakitug
- Du vakitug dose 2Treatment being tested
SC injection as per protocol
Treatment: Duvakitug
- Du vakitug dose 3Treatment being tested
SC injection as per protocol
Treatment: Duvakitug
- PlaceboPlacebo, for comparison
SC injection as per protocol
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Phase 3, Maintenance Study to Evaluate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Plain-language title
- Tests duvakitug in adults with active Crohn's disease over timeGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Criteria questions
- Built from NCT07184944, who can take part
- Record updated
- 21 October 2026